Peter Sandner studied Pharmaceutical Sciences at the University of Regensburg. After his practical year in a public and hospital pharmacy he started a PhD followed by post-doctoral period at the Institute of Physiology at the University of Regensburg.  He joined Bayer Pharmaceuticals as Lab Head at the Institute of Cardiovascular Pharmacology at Wuppertal in 2001. Within Bayer, he continued his research on cyclic nucleotides and cGMP by nonclinical profiling of cGMP-increasing therapeutic principles especially phosphodiesterase inhibitors but also stimulators and activators of the soluble guanylyl cyclase (sGC). He was appointed to a Chief Scientist within Bayer in 2016 and became Extraordinary (Apl.) Professor at the Hannover Medical School in 2020. He is based at Wuppertal in the Bayer Research Center, working in Cardiovascular and Renal Research and Early Development and is responsible for the nonclinical research with sGC stimulators like riociguat and vericiguat and sGC activators like runcaciguat and nurandociguat in various therapeutic areas.